Soleno Shares Are Trading Lower After FDA Demands Additional Study For DCCR Program In Prader-Willi Syndrome

Soleno Therapeutics Inc (NASDAQ: SLNO) drops in premarket trading after the FDA said that it would require an additional controlled clinical trial for DCCR (diazoxide choline) in Prader-Willi Syndrome (PWS).

  • The agency said that this additional study would help support the DCCR marketing application.
  • Regarding the potential adequacy of DCCR data for marketing application, the company submitted additional analyses to the FDA from Phase 3 trial, DESTINY PWS (C601), in November last year.
  • These data analyses showed statistically significant changes for DCCR compared to placebo in the primary and key secondary endpoints.
  • The company says that it is currently evaluating the appropriate next steps for our DCCR program.
  • PWS is characterized by a constant sense of hunger (hyperphagia), which leads to severe obesity resulting in physical, mental, and behavioral problems.
  • Price Action: SLNO shares tanked 37.2% at $1.69 in premarket trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralPrader-Willi Syndrome
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!